Results 71 to 80 of about 4,078 (132)

PRRT for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). [PDF]

Endocr Relat Cancer
Corbett V, Gupta G, Chauhan A.
europepmc   +1 more source

Comparing Response Evaluation Methods for PRRT in Neuroendocrine Tumors: Insights from an Exploratory Study. [PDF]

Cancers (Basel)
Guglielmo P, Carnaghi C, Bertuzzi AF, Laffi A, Damiani S, Riva UC, Olivieri M, Marenco M, Evangelista L.   +8 more
europepmc   +1 more source

Multimodal Deep Learning for Prediction of Progression-Free Survival in Patients with Neuroendocrine Tumors Undergoing ¹⁷⁷Lu-Based Peptide Receptor Radionuclide Therapy. [PDF]

Cancers (Basel)
Baur S, Ruhwedel T, Böke E, Kobus Z, Lishkova G, Wetz C, Amthauer H, Roderburg C, Tacke F, Rogasch JM, Samek W, Jann H, Ma J, Eschrich J.   +13 more
europepmc   +1 more source

Circulating Tumor DNA Monitoring in Peptide Receptor Radionuclide Therapy-Treated Patients With Gastroenteropancreatic Neuroendocrine Tumors. [PDF]

JCO Precis Oncol
Bogdani C, Karimi A, Li R, Atkinson EC, Oberstein PE, Siolas D.   +5 more
europepmc   +1 more source

Relationship between absorbed dose and SUV derived from SPECT/CT imaging and dose-response in patients with neuroendocrine tumors treated with [¹⁷⁷Lu]Lu-DOTA-TATE. [PDF]

EJNMMI Res
Liu F, Yang H, Zhang J, Li J, Qiao Y, Chen J, Song S.   +6 more
europepmc   +1 more source

Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions. [PDF]

Eur J Nucl Med Mol Imaging
Virgolini IJ, Di Santo G, Santo G.
europepmc   +1 more source

Occurrence and Management of Acute, Subacute, and Delayed Toxicities in Patients with GEP-NETs Following Treatment with Radioligand Therapy. [PDF]

Cancers (Basel)
El-Haddad G, Gardner L, Kim H, Soares HP.   +3 more
europepmc   +1 more source

Reproductive and sexual sequelae of neuroendocrine tumour therapies: an under-recognised challenge. [PDF]

Endocr Relat Cancer
Shekhda KM, Shah PM, Biddanda A, Grossman A, Caplin M.   +4 more
europepmc   +1 more source

Small bowel obstruction from metastatic small intestinal neuroendocrine tumor managed solely with somatostatin analog. [PDF]

JCEM Case Rep
Taher Z, Andijani R, Radi S.
europepmc   +1 more source

Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II study. [PDF]

Ann Nucl Med
Kobayashi N, Ono H, Okubo N, Akahoshi K, Kudo A, Ban D, Ichikawa Y.   +6 more
europepmc   +1 more source